skip to main content

Texas Vaccine Outreach and Education Grant - Round 2

Inform, connect and protect your community.

The purpose of the second round of the Texas Vaccine Outreach and Education Grant Program is to fund projects that ensure greater access and knowledge of COVID-19 vaccines through education and outreach to populations disproportionately affected by COVID-19. Grantees will be awarded funds to engage their community in proactive COVID-19 vaccine education and outreach activities with the goal of increasing the number of people fully vaccinated for COVID-19 in Texas.

Those who are hesitant to receiving a COVID-19 vaccine could have questions ranging from what the process was for creating the vaccines to wanting more information about the vaccine’s safety and effectiveness. Community-based organizations are critical to informing communities about the COVID-19 vaccines and increasing vaccine confidence for those who are still deciding whether to get vaccinated.

We invite statewide organizations, academic institutions, and community-based organizations of all sizes who have strong, direct relationships with the populations they serve to apply for funding. Engagement activities such as hosting events, canvassing door-to-door, or providing other services directly to the community are greatly valued. Even if your organization’s mission or regular operations aren’t vaccine or public-health related, Texas A&M University Health Science Center and the Department of State Health Services are here to provide guidance, toolkits, resources, and other technical assistance throughout the project timeline.

COVID-19 vaccines currently available in the United States have been shown to be highly effective at preventing and mitigating severe disease from COVID-19. Preventing disparities in access to and knowledge of COVID-19 vaccines is important to reduce the disproportionate impacts of the virus. Lower vaccination rates among some groups leaves them at increased risk for infection, especially as new variants spread.

Priority will be given to applicants who are: 

  • Statewide organizations proposing targeted community interventions addressing communities of color, rural communities, and/or Texans with disabilities
  • Groups or organizations focusing on serving parents of children in Texas regarding COVID-19 vaccine safety and efficacy
  • Groups or organizations focusing on one or more of ten counties in Texas with low vaccination rates (Bell, Bowie, Ector, Grayson, Jefferson, Johnson, McLennan, Parker, Tom Green, and/or Wichita)
  • Groups or organizations focusing on serving Tribal Nations

For more information email us at .

Read the press release from the Texas Department of State Health Services and Texas A&M Health HERE


Funded Organizations (Round 2)
American Muslim Today Foundation, Inc.  $181,789.00
Association of Nigerian Women Entrepreneurs and Professionals, ANWEP  $558,132.00
Back to Eden Fellow Program  $198,932.00
Bandera County Committee on Aging, Inc., DBA The Silver Sage  $335,768.00
Bexar County Community Health Collaborative  $375,036.00
Boys and Girls Clubs of Greater Houston  $328,299.00
Clover Educational Consulting Group, Inc.  $465,647.00
Concho Valley Center for Human Advancement, DBA MHMR Concho Valley  $150,295.00
El Buen Samaritano Episcopal Mission  $250,085.00
Foundation Communities, Inc.  $155,067.00
Harris County Hospital District  $250,042.00
Homeward Bound, Inc.  $368,283.00
Ibn Sina Foundation, Inc.  $316,790.00
Mano Amiga  $309,397.00
Manos Unidas  $319,236.00
Meadows Mental Health Policy Institute  $999,993.00
Sewa International, Inc.  $642,987.00
Special Health Resources for Texas, Inc.  $314,134.00
Tarleton State University  $158,400.00
Texas A&M University Center for Population Health and Aging  $799,148.00
Texas A&M University Coastal Bend Health Education Center  $720,403.00
Texas A&M University College of Medicine  $499,934.00
Texas A&M University School of Public Health  $865,577.00
Texas Familias Council  $427,936.00
Texas Network of Youth Services, Inc.  $421,160.00


Yes, people who join a study get compensated for their time and inconvenience. The amount per visit varies depending on how long the visit is and the procedures that take place. The amount also varies from city to city, because the cost of living is different between large metropolitan areas compared to smaller towns and rural areas. Details about compensation will be explained when a person goes through the informed consent process at a local clinic to join a study.
College students are an ideal population for the study because large numbers of COVID-19 cases have been reported on numerous campuses throughout the U.S., with a nationwide survey reporting more than 397,000 cases counted at 1,800+ universities after colleges reopened in the fall of 2020. And, while there are many populations who have a high risk of COVID-19 infection, young people are particularly at risk for getting and spreading the virus. For example, according to a CDC Morbidity and Mortality Weekly Report, between August and September 2020, COVID-19 cases among young people aged 18-22 years increased 55% nationally and during June-August 2020, young people aged 20-29 years had the highest incidence of disease in the U.S., accounting for more than 20% of all confirmed cases.
No. That type of study design is known as a challenge study, which is not what we are conducting. We expect that some people will be exposed to the virus in their everyday lives, and may become sick, but are not intentionally infecting study participants. The Moderna vaccine does not include live, weakened or whole virus.
No, it is not possible for the mRNA vaccines to impact a person’s DNA in any way. mRNA is a piece of genetic code that tells the muscle cells to make the spike protein from SARS-CoV-2 and display it for the immune system to see. It’s like a recipe for making food, with step by step instructions to follow. The vaccine doesn’t have any real ingredients that could cause infection, just the instructions. The vaccine goes to work in the outer part of muscle cells, and does not cross into the nucleus, where people’s DNA is located. You may also know that the mRNA vaccines need to be stored at very cold temperatures to keep them stable. This is because when they heat up, the mRNA starts to fall apart. Once the vaccine is given to a person, it starts to heat up in the body and dissolves within 1-3 days.
Yes. People who want to get pregnant in the future may receive the COVID-19 vaccine.
Based on current knowledge, experts believe that COVID-19 vaccines are unlikely to pose a risk to a person trying to become pregnant in the short or long term. Scientists study every vaccine carefully for side effects immediately and for years afterward, and people who get vaccinated track their symptoms. The COVID-19 vaccines are being studied carefully now, and the side effects data will continue to be studied for many years, similar to other vaccines.
There is currently no evidence that antibodies formed from COVID-19 vaccination cause any problems with pregnancy. In addition, there is no evidence suggesting that fertility problems are a side effect of ANY vaccine. People who are trying to become pregnant now or who plan to try in the future may receive the COVID-19 vaccine when it becomes available to them.
Rest, and in some cases, over-the-counter medication (examples: acetaminophen, ibuprofen) might help if you have a fever or aches and pains. These medicines should not be used before getting a vaccine, only afterward to treat side effects.
The risk of allergic reaction is extremely low. Talk to your doctor if you have a history of allergic reactions or anaphylaxis before getting a COVID-19 vaccine. There are guidelines in place that may require you to be observed for more than 15 minutes after vaccination in the event of a reaction so that it can be immediately treated.
Relevant statistics
Moderna: 10 cases of allergic reaction with 4 million doses delivered (0.0003%). In 9 of those 10 cases, the reaction occurred within 15 minutes.
While the study will enroll college students over a five-month period, results are expected later this year and are critical to explain the extent to which the vaccine may prevent asymptomatic infection and onward transmission of SARS-CoV-2. With the U.S. having the highest number of infections and deaths from COVID-19 disease of any nation in the world, this study is vital to making informed public policy decisions in the coming year. Should the vaccine be found to work primarily by reducing symptoms – preventing severe disease and saving the lives of those vaccinated but not curbing ongoing viral transmission — studies project that the number of asymptomatic infections could rise, which would increase transmission and prolong the pandemic.
IRB Number 2020-0432F IRB Approval Date:1/20/2021